Literature DB >> 22467146

Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease.

George P Christophi1, Rong Rong, Philip G Holtzapple, Paul T Massa, Steve K Landas.   

Abstract

BACKGROUND: Cytokine signaling pathways play a central role in the pathogenesis of inflammatory bowel disease (IBD). Ulcerative colitis (UC) and Crohn's disease (CD) have unique as well as overlapping phenotypes, susceptibility genes, and gene expression profiles. This study aimed to delineate patterns within cytokine signaling pathways in colonic mucosa of UC and CD patients, explore molecular diagnostic markers, and identify novel immune mediators in IBD pathogenesis.
METHODS: We quantified 70 selected immune genes that are important in IBD signaling from formalin-fixed, paraffin-embedded (FFPE) colon biopsy samples from normal control subjects and UC and CD patients having either severe colitis or quiescent disease (n = 98 subjects). We utilized and validated a new modified real-time reverse-transcription polymerase chain reaction (RT-PCR) technique for gene quantification.
RESULTS: Expression levels of signaling molecules including IL-6/10/12/13/17/23/33, STAT1/3/6, T-bet, GATA3, Foxp3, SOCS1/3, and downstream inflammatory mediators such as chemokines CCL-2/11/17/20, oxidative stress inducers, proteases, and mucosal genes were differentially regulated between UC and CD and between active and quiescent disease. We also document the possible role of novel genes in IBD, including SHP-1, IRF-1,TARC, Eotaxin, NOX2, arginase I, and ADAM 8.
CONCLUSIONS: This comprehensive approach to quantifying gene expression provides insights into the pathogenesis of IBD by elucidating distinct immune signaling networks in CD and UC. Furthermore, this is the first study demonstrating that gene expression profiling in FFPE colon biopsies might be a practical and effective tool in the diagnosis and prognosis of IBD and may help identify molecular markers that can predict and monitor response to individualized therapeutic treatments.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467146      PMCID: PMC3407828          DOI: 10.1002/ibd.22957

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  75 in total

1.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis.

Authors:  Luca Pastorelli; Rekha R Garg; Sharon B Hoang; Luisa Spina; Benedetta Mattioli; Melania Scarpa; Claudio Fiocchi; Maurizio Vecchi; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

2.  Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease.

Authors:  David-G Cox; J-Bart-A Crusius; Petra-H-M Peeters; H-Bas Bueno-de-Mesquita; A-Salvador Pena; Federico Canzian
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

3.  Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway.

Authors:  J Rouleau; A R MacLeod; M Szyf
Journal:  J Biol Chem       Date:  1995-01-27       Impact factor: 5.157

4.  Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment.

Authors:  Ingrid Arijs; Gert De Hertogh; Kathleen Machiels; Kristel Van Steen; Katleen Lemaire; Anica Schraenen; Leentje Van Lommel; Roel Quintens; Gert Van Assche; Séverine Vermeire; Frans Schuit; Paul Rutgeerts
Journal:  Am J Gastroenterol       Date:  2011-02-15       Impact factor: 10.864

5.  STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-induced colon epithelial cell dysfunction.

Authors:  Michael J Rosen; Mark R Frey; M Kay Washington; Rupesh Chaturvedi; Lindsay A Kuhnhein; Poojitha Matta; Frank L Revetta; Keith T Wilson; D Brent Polk
Journal:  Inflamm Bowel Dis       Date:  2011-02-09       Impact factor: 5.325

Review 6.  Genomic views of STAT function in CD4+ T helper cell differentiation.

Authors:  John J O'Shea; Riitta Lahesmaa; Golnaz Vahedi; Arian Laurence; Yuka Kanno
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

7.  Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness.

Authors:  J Deshane; J W Zmijewski; R Luther; A Gaggar; R Deshane; J-F Lai; X Xu; M Spell; K Estell; C T Weaver; E Abraham; L M Schwiebert; D D Chaplin
Journal:  Mucosal Immunol       Date:  2011-04-06       Impact factor: 7.313

8.  Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.

Authors:  Jan Wehkamp; Klaus Fellermann; Klaus R Herrlinger; Steffi Baxmann; Klaus Schmidt; Bettina Schwind; Michael Duchrow; Charlotte Wohlschläger; Alfred C Feller; Eduard F Stange
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-07       Impact factor: 2.566

9.  Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1.

Authors:  P T Massa; C Wu
Journal:  J Interferon Cytokine Res       Date:  1998-07       Impact factor: 2.607

10.  Central neuroinvasion and demyelination by inflammatory macrophages after peripheral virus infection is controlled by SHP-1.

Authors:  George P Christophi; Paul T Massa
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

View more
  49 in total

1.  The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications.

Authors:  Tomer Adar; Shimon Shteingart; Ami Ben-Ya'acov; Ariella Bar-Gill Shitrit; Dan M Livovsky; Shimrit Shmorak; Mahmud Mahamid; Bernardo Melamud; Fiona Vernea; Eran Goldin
Journal:  Dig Dis Sci       Date:  2016-02-13       Impact factor: 3.199

2.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

3.  No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects.

Authors:  Mustafa Hartavi; Selim Giray Nak; Barbaros Oral; Adem Deligönül
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

Review 4.  Experimental appendicitis and appendectomy modulate the CCL20-CCR6 axis to limit inflammatory colitis pathology.

Authors:  Rajkumar Cheluvappa
Journal:  Int J Colorectal Dis       Date:  2014-07-01       Impact factor: 2.571

5.  Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis.

Authors:  George P Christophi; Tiffany Caza; Christopher Curtiss; Divya Gumber; Paul T Massa; Steve K Landas
Journal:  Exp Mol Pathol       Date:  2014-04-21       Impact factor: 3.362

6.  Sphingosine-1-phosphate in inflammatory bowel disease and colitis-associated colon cancer: the fat's in the fire.

Authors:  Jung H Suh; Julie D Saba
Journal:  Transl Cancer Res       Date:  2015-10-01       Impact factor: 1.241

7.  Increased IL-17A/IL-17F expression ratio represents the key mucosal T helper/regulatory cell-related gene signature paralleling disease activity in ulcerative colitis.

Authors:  Yoichiro Iboshi; Kazuhiko Nakamura; Keita Fukaura; Tsutomu Iwasa; Haruei Ogino; Yorinobu Sumida; Eikichi Ihara; Hirotada Akiho; Naohiko Harada; Makoto Nakamuta
Journal:  J Gastroenterol       Date:  2016-05-13       Impact factor: 7.527

8.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Authors:  Mehdi Rashighi; Priti Agarwal; Jillian M Richmond; Tajie H Harris; Karen Dresser; Ming-Wan Su; Youwen Zhou; April Deng; Christopher A Hunter; Andrew D Luster; John E Harris
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

Review 9.  Emerging neuropeptide targets in inflammation: NPY and VIP.

Authors:  Bindu Chandrasekharan; Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

Review 10.  Therapy with stem cells in inflammatory bowel disease.

Authors:  María Del Pilar Martínez-Montiel; Gonzalo Jesús Gómez-Gómez; Ana Isabel Flores
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.